Ventyx Biosciences (VTYX)
(Delayed Data from NSDQ)
$2.05 USD
-0.02 (-0.97%)
Updated Oct 10, 2024 04:00 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Ventyx Biosciences, Inc. [VTYX]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Recap: Three Phase 2 Trials Targeting NLRP3 Inhibition Expected to Initiate in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We Are Unsurprised by Discontinuation of VTX958 Development Post-Phase 2 CD Failure
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Competitor NLRP3 Data Show Reduction in CRP, Though Significance Unknown
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
VTX3232 Preclinical Obesity Data Provide POC Though a Combo Approach May be Needed
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: VTX3232 Obesity Mouse Data Expected in 2Q24; Phase 2a Trial Initiations on Track for 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
NLRP3 Inhibitors Present Opportunities in Cardiovascular Diseases and Neuroinflammation; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Recap; Several Clinical Data Updates to be Presented at Investor Event on March 11; PT Updated to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Competitor Preclinical Publication of NLRP3 Inhibitors Demonstrates Potential Efficacy in Treating Obesity
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for VTYX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: Several Pipeline Updates Expected in 1Q24; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Endoscopic Remission Is a Highlight in Positive Phase 2 VTX002 UC Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: Two Significant Catalysts Including Phase 2 UC and Psoriasis Data Expected in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Best Oral Therapy for Psoriasis is Still Up for Grabs, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Recap: 2H23 Catalysts Include VTX002 UC Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Take: All Timelines Remain on Track For an Eventful 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Our Views on TAK-279 Phase 2 Data and Read-Through to VTX958
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2023 is the Year of Execution With Initial Fruition Expected in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Takeda Acquisition of Nimbus'' TYK2 Inhibitor Underscores That VTX958 is Undervalued
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Ventyx Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Take: Focus Is Now on Advancing the Pipeline Into Phase 2 Studies and VTX002 Top-Line Data in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E